Inhibrx Biosciences, Inc. (INBX) fair value: what the stock is really worth
As of Nov 20, 2026: fair value (intrinsic value) of Inhibrx Biosciences, Inc. stock $26.77, price $68.97, that is 61.2% below the price, quality 37 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently applies, it draws on revenue and assets compared with similar companies. Updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Inhibrx Biosciences, Inc.
INBX · USFar too expensive (fair value 61% below the price) and weak company, but rising price: meets 1 of 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 22, 2026.
How to read this chart
30‑month range $10.84 – $141.84 · fair‑value band $20.08 – $33.46 · the $68.97 price screens above the $26.77 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 22, 2026.
Every Wednesday you see whether Inhibrx Biosciences is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions.
Show moreShow less
Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung cancer cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma.
Inhibrx Biosciences, Inc. was incorporated in 2024 and is based in La Jolla, California.
Stock analysis
Inhibrx Biosciences, Inc. (INBX) currently trades at $68.97, while our estimate is $26.77, 61% below the price, so the stock looks overvalued today.
Show more
Valuation
None of our valuation models currently applies to this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: $20.08 (bear) to $33.46 (bull), the price of $68.97 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 37/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Inhibrx Biosciences, Inc. reported revenue of $1.3M in FY2025 versus $7.1M in FY2021, a compound −34.6%/yr. Reported net income was −$140M in FY2025.
Key figures
Market cap $1.1B Small · EPS (TTM) $-8.43 · Return on equity −1,774% · Return on assets (EBIT) −88.4% (5-year average) · Operating margin −6,287% · Revenue (TTM) $2.0M · Free cash flow −$130M · Net cash $17.2M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 23 out of 100 (low confidence).
What moves the price
The share trades about 51% below its 52-week high and 18% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −4% fair-value upside, at −61%, INBX screens richer than that median.
Fair Value
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Insider trades
In the last 6 months, 3 officers or directors bought shares worth $6.3M, most recently on Oct 14, 2026. Over the same period, one person sold shares worth $279,015. Buying cluster
- BuyMark LappeChief Executive Officer, Director3× since Sep 8, 2026: 45,040 shares, avg. $99.76$4.5MOct 14, 2026
- BuyJon Faiz KayyemDirector3× since Sep 8, 2026: 15,000 shares, avg. $104.51$1.6MSep 23, 2026
- SaleKimberly ManhardDirector2× since Sep 8, 2026: 2,500 shares, avg. $111.61$279,015Sep 15, 2026
- BuyDouglas ForsythDirector2,500 shares at $114.65$286,625Sep 8, 2026
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Source: SEC Form 4, as of Nov 20, 2026. All filings at the SEC ↗
Revenue & earnings trend
Earlier news
- Inhibrx’s Cancer Drug Nearly Doubled Response Rate, So Why Did the Stock Fall?
- Inhibrx Founder and CEO Mark Lappe Buys 25,000 Shares for $2.6 Million. What Does His Confidence Tell Investors?
- 6 Biotech Stocks That Delivered Stunning Gains: INBX +700%, PVLA +500%, MBX +300%, ABSI +200% & More
- Inhibrx Biosciences (INBX) Announces Positive Interim Results From Phase 2 Portion of HexAgon Study
Compare Inhibrx Biosciences, Inc. with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 856 stocks
Valuation Multiplesvs Biotechnology median · lower = cheaper
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Revenue growth by industry
- PEG ratio by industry
- Piotroski F-Score screener with fair value
- Undervalued stocks: US Stocks
- Valuation of the USA market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc REGN | $920.69 | $1,275.02 | +38% | vs INBX |
| Vertex Pharmaceuticals Incorporated VRTX | $515.02 | $566.52 | +10% | vs INBX |
| Samsung Biologics Co 207940 | ₩1,355,000 | ₩1,490,500 | +10% | vs INBX |
| argenx SE ARGX | $925.70 | $908.40 | −2% | vs INBX |
| CSL Limited CSL | A$197.29 | A$188.80 | −4% | vs INBX |
| BeOne Medicines AG 6160 | HK$230.80 | HK$152.92 | −34% | vs INBX |
| Moderna, Inc MRNA | $195.00 | $122.98 | −37% | vs INBX |
| Revolution Medicines, Inc RVMD | $161.20 | $83.14 | −48% | vs INBX |
| Celltrion, Inc 068270 | ₩213,000 | ₩74,574 | −65% | vs INBX |
| Royalty Pharma plc RPRX | $68.45 | $19.01 | −72% | vs INBX |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Inhibrx Biosciences, Inc. (INBX) overvalued or undervalued?
What is the fair value of INBX?
What is the quality score of INBX?
What is the price target for Inhibrx Biosciences, Inc. (INBX)?
What is the Inhibrx Biosciences, Inc. stock forecast for 2026?
What is the revenue of Inhibrx Biosciences, Inc. (INBX)?
What is the intrinsic value of Inhibrx Biosciences, Inc. (INBX)?
Is Inhibrx Biosciences, Inc. stock overvalued or undervalued in 2026?
Is fair value the same as the market price of INBX?
How much is Inhibrx Biosciences, Inc. worth?
What do the bullish and bearish scenarios say about INBX?
How solid is the balance sheet of Inhibrx Biosciences, Inc. (INBX)?
How far is INBX from its 52-week high?
Which stocks are comparable to Inhibrx Biosciences, Inc.?
Is Inhibrx Biosciences, Inc. stock attractive at the current price?
Is it still worth investing in stocks now?
What is the share price of Inhibrx Biosciences, Inc. (INBX)?
What should I pay attention to with Inhibrx Biosciences, Inc. right now?
Key figures of Inhibrx Biosciences, Inc.
How large is the market capitalisation of Inhibrx Biosciences, Inc. (INBX)?
What are the earnings per share of Inhibrx Biosciences, Inc. (INBX)?
What is the return on equity of Inhibrx Biosciences, Inc. (INBX)?
What is the EBIT return on assets of Inhibrx Biosciences, Inc. (INBX)?
What is the operating margin of Inhibrx Biosciences, Inc. (INBX)?
How much free cash flow does Inhibrx Biosciences, Inc. (INBX) generate?
How much net cash does Inhibrx Biosciences, Inc. (INBX) hold?
Watch Inhibrx Biosciences, Inc. in the live analysis
One click puts Inhibrx Biosciences, Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.